Actively Recruiting
Comparison of Virtue Sirolimus AngioInfusion Balloon and AGENT Paclitaxel Drug-Coated Balloon in Treating Coronary Artery In-Stent Restenosis A Randomized Multi-Center Study
Led by Orchestra BioMed, Inc · Updated on 2026-10-22
740
Participants Needed
22
Research Sites
208 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the clinical outcomes of two medical devices, the Virtue Sirolimus AngioInfusion Balloon SAB and the AGENT Paclitaxel Drug-Coated Balloon DCB, in treating coronary artery in-stent restenosis ISR. This study is a prospective, multi-center, single-blind, randomized trial designed to determine whether the Virtue SAB is not inferior to the AGENT DCB for this condition. Participants will be randomly assigned to receive either the Virtue SAB or the AGENT DCB as part of a percutaneous coronary intervention procedure. Both devices are used to treat ISR, with the Virtue SAB delivering sirolimus and the AGENT DCB delivering paclitaxel. The study compares these two treatments directly, with each balloon covering the affected lesion completely during the angioplasty procedure. During the study, participants will be monitored for up to 12 months, with the primary outcome being Target Lesion Failure TLF measured at 12 months post-treatment. Follow-up visits will include clinical assessments to evaluate the success of the treatment and monitor for any complications. The study aims to collect detailed clinical data over this period to assess the safety and performance of both devices in treating coronary artery ISR.
CONDITIONS
Brief Title
Virtue® SAB in the Treatment of Coronary ISR Trial
Research Team
H
Hans-Peter Stoll, MD, PHD
A
Amy Berman, MPH
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here